What is Leerink Partnrs' Forecast for CLDX Q1 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for Celldex Therapeutics in a report issued on Thursday, February 13th. Leerink Partnrs analyst T. Smith expects that the biopharmaceutical company will post earnings per share of ($0.65) for the quarter. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics' Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.94) EPS.

CLDX has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. UBS Group began coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $60.22.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX traded down $0.16 during mid-day trading on Friday, reaching $22.54. 541,371 shares of the company's stock were exchanged, compared to its average volume of 985,970. Celldex Therapeutics has a one year low of $20.91 and a one year high of $53.18. The firm has a market capitalization of $1.50 billion, a PE ratio of -8.77 and a beta of 1.60. The business's fifty day simple moving average is $24.63 and its two-hundred day simple moving average is $29.62.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares in the last quarter. KBC Group NV boosted its stake in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after purchasing an additional 495 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $81,000. AlphaQuest LLC boosted its stake in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.